Podcasts about assistant member

Claire L. Carter, Ph.D., is an Assistant Member of the Center for Discovery and Innovation; Assistant Professor of Pathology at Hackensack Meridian School of Medicine; and Co-Director of the Mass Spectrometry and Analytical Pharmacology Shared Resource at the NCI-designated Georgetown Lombardi Comprehensive Cancer Center.Dr. Carter completed her Ph.D. in Chemistry at the University of Birmingham, UK, under the supervision of Professor Josephine Bunch. She then moved to the US for a postdoctoral appointment at the University of Maryland Baltimore, where she worked on normal tissue radiation injury. At the Hackensack Meridian Center for Discovery and Innovation, Dr. Carter has built a translational pediatric neuro-oncology research program in partnership with Dr. Derek Hanson, Director of Pediatric Neuro-oncology, Joseph M. Sanzari Children's Hospital, Hackensack University Medical Center.Dr. Carter possesses a rare translational background that combines expertise in bioanalytical chemistry, clinical histopathology and biomedical science. Her group are using next generation imaging techniques to develop a deep understanding of the biological and transitional states of tumor cells as shaped by their spatiotemporal location within patient tumors and preclinical models. Their focus is on targeting lipid signaling and metabolism for less toxic and more efficacious treatments in highly aggressive pediatric brain tumors. In addition to using mass spectrometry imaging for intratumoral pharmacokinetic/pharmacodynamic (PK/PD) studies to identify more efficacious treatment regimens that can be rapidly translated into clinic gain.You can also get involved with the Gold Ribbon Kids Cancer Foundation or the National Pediatric Cancer Foundation through fundraising, volunteering, promoting awareness, or contributing to pediatric cancer research. Visit goldribbon-kids.org or nationalpcf.org for more informationTo contact Tiffany, please email info@goldribbon-kids.orgTo contact Kelly, please email kgoddard@nationalpcf.orgSupport the show

The Greg and Dan Show with special guest Lee Hall welcomes Dr. Beth Stewart of St. Jude Children's Hospital for a conversation on the work, research, and impact of St. Jude in children's lives.  Dunlap native Dr. Beth is a pediatric hematologist-oncologist and Assistant Member at St. Jude in the Solid Tumor Division of the Department of Oncology.See omnystudio.com/listener for privacy information.

In this episode "ASTCT Talks,” hosts Rebecca Epperly, MD, and Aimee Talleur, MD, from St. Jude Children's Research Hospital, dive into the pioneering realm of CAR T-cell therapy and its late effects on pediatric patients. The discussion unfolds at the intersection of innovation and caution, highlighting the recent sessions from the 2024 Tandem meetings. They explore the emerging challenges and lack of data concerning long-term impacts of this revolutionary treatment, particularly in pediatric, adolescent, and young adult populations. This episode sheds light on both the immense potential and the imperative need for comprehensive studies to better understand and mitigate the long-term consequences of cellular therapies in treating high-risk malignancies. About Dr. Rebecca Epperly, MD Dr. Rebecca Epperly is an Instructor in the Department of Bone Marrow Transplantation and Cellular Therapy (BMTCT) at St. Jude Children's Research Hospital. After gaining undergraduate degrees in biochemistry (BS) and music performance (BA), she received an MD from the University of Iowa Carver College of Medicine. She then completed pediatrics residency at the UPMC Children's Hospital of Pittsburgh and fellowships in pediatric hematology/oncology and BMTCT at St. Jude. As a clinician scientist, she is now working to improve outcomes for pediatric patients with high-risk malignancies using cellular based immunotherapy, with a focus on developing early-phase CAR T cell studies and evaluating the delayed effects of novel therapies. About Dr. Aimee Talleur, MD Dr. Aimee Talleur is an Assistant Member in the Department of Bone Marrow Transplantation and Cellular Therapy (BMTCT) at St. Jude Children's Research Hospital, specializing in the clinical investigation of novel immunotherapies for the treatment of high-risk malignant disorders. She completed her BA at Union College, MD at SUNY Upstate Medical University, pediatric residency at Children's National Medical Center, and fellowships in pediatric hematology/oncology and BMTCT at St. Jude. As a clinician scientist, Dr. Talleur focuses on the advancement of novel cellular therapies through early-phase clinical trials, including CAR T cell therapy. Additionally, her work includes the evaluation of acute and long-term toxicities of this immunotherapy approaches, seeking to better define such toxicities to inform upon predictive and intervention strategies.

This episode is sponsored is by BTG Pharmaceuticals Dr. Michael Bishop is an Assistant Member in the Solid Tumor Division of the Department of Oncology at St. Jude Children's Hospital in Memphis, TN. His clinical practice focuses primarily on the management of children and young adults with bone and soft tissue sarcomas, and his research interests are dedicated to the development of prospective clinical trials for the treatment of osteosarcoma. Dr. Bishop graduated from the University of Arkansas College of Medicine and completed his pediatric residency at Children's Mercy Kansas City, and fellowship in pediatric hematology and oncology at Cincinnati Children's Hospital Medical Center. Dr. Bishop is a member of the Children's Oncology Group Bone Tumor Committee and is the Study Chair for AOST2032, a prospective trial assessing the feasibility and efficacy of combining a multi-targeted tyrosine kinase inhibitor with chemotherapy for newly diagnosed osteosarcoma. --- What We Do at MIB Agents: PROGRAMS: End-of-Life MISSIONS Gamer Agents Agent Writers Prayer Agents Healing Hearts - Bereaved Parent and Sibling Support Ambassador Agents - Peer Support Warrior Mail Young Adult Survivorship Support Group EDUCATION for physicians, researchers and families: OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma MIB Book: Osteosarcoma: From our Families to Yours RESEARCH: Annual MIB FACTOR Research Conference Funding multiple $100,000 and $50,000 grants annually for OS research MIB Testing & Research Directory The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. https://www.mibagents.org​ Help support MIB Agents, Donate here https://give-usa.keela.co/embed/YAipuSaWxHPJP7RCJ SUBSCRIBE for all the Osteosarcoma Intel

Editor-in-Chief Dr. Sue Yom is joined this month by co-host Dr. Danielle Margalit, the Red Journal's Head and Neck Section Editor and Associate Professor of Radiation Oncology at Harvard Medical School. Guests are Dr. Adam Garden, Professor of Radiation Oncology at UT MD Anderson Cancer Center, who is the first author of an article in this month's issue, "Final Report of NRG Oncology RTOG 0022: A Phase 1/2 Study of Conformal and Intensity Modulated Radiation for Oropharyngeal Cancer"; Dr. Michelle Echevarria, Assistant Member in the Department of Radiation Oncology at Moffitt Cancer Center and first author of another article printing this month, "Phase 1 Dose Escalation of Stereotactic Body Radiation Therapy and Concurrent Cisplatin for Reirradiation of Unresectable, Recurrent Squamous Cell Carcinoma of the Head and Neck"; and Dr. Robert Chin, Associate Professor at UCLA Radiation Oncology and supervising author of a third article in the October issue, "High Recurrence for HPV-Positive Oropharyngeal Cancer With Neoadjuvant Radiation Therapy to Gross Disease Plus Immunotherapy: Analysis From a Prospective Phase Ib/II Clinical Trial."

Dr. Dan Nahrwold had heard of CLC's life-changing "All In" discipleship curriculum but experiencing it for himself surpassed all his expectations.Dan shares about how God planted seeds in his life several years earlier, and how those seeds led to eventually starting his own "All In" group after moving to Tampa, FL. We spend some time discussing the significance of relationships in men's discipleship and how that accountability impacts our approach to work and our careers.Dr. Daniel Nahrwold is an Assistant Member in the Moffitt Cancer Center Department of Anesthesiology. Dr. Nahrwold earned his MD at the Indiana University School of Medicine. He then completed an Anesthesiology Residency at Vanderbilt University Medical Center followed by a Critical Care Medicine Fellowship at the University of California, San Francisco.MEN'S WEEKEND DETAILS:Empowered Manhood Men's Weekend  (https://www.empoweredmanhood.com/event-details/empowered-manhood-mens-weekend)ISRAEL EXPERIENCE:Empowered Manhood Israel Experience (https://registernow.ittworld.com/)Tour Code: Empower24Spouses are welcome!Contact Mike Hatch: mhatch@clchq.orgOrder Mike's book, Manhood: Empowered by the Light of the GospelJoin the Empowered Manhood Facebook GroupListen to the introduction and first chapter of Mike's book:https://podcasts.apple.com/us/podcast/special-edition-manhood-empowered-by-the-light-of/id1584970534?i=1000603237979CLC Website: https://www.clchq.org/Contact Chris Bolinger: https://chrisbolinger.com/author/Chris' Devotionals:Daily Strength for Men: A 365-Day Devotional52 Weeks of Strength for Men

As clinicians continue to seek new ways to provide the best patient care for patients with myeloproliferative neoplasms, a group of rare hematological cancers which can be challenging to treat, hear how recent guideline and treatment updates by the National Comprehensive Cancer Network (NCCN) can optimize care for patients with myeloproliferative neoplasms. In this episode, CANCER BUZZ speaks with Andrew Kuykendall, MD, assistant member of the Department of Malignant Hematology at Moffitt Cancer Center in Tampa, Fla. about the impact of these new guidelines. “Every single patient is very different in the symptoms they present with, the duration of the disease, and what their goals are in receiving therapy. Ultimately, that often means that we don't have a one-size-fits-all treatment strategy…Instead, we have a variety of treatment options that can provide different benefits for patients and when you have that, it merely comes down to what makes sense for the patient, what makes sense for the disease, what makes sense for the patient's family, and what you feel as a physician is the most appropriate for the patient.” – Andrew Kuykendall, MD This is the fourth video podcast in a four-episode series on myeloproliferative neoplasms in connection with the education program Advancing Care for Patients with Myeloproliferative Neoplasms (MPNs). This episode is supported by Incyte. Guests: Andrew Kuykendall, MD,  Assistant Member, Department of Malignant Hematology Moffitt Cancer Center Tampa, FL Resources: Myeloproliferative Neoplasms (cancersupportcommunity.org) National Comprehensive Cancer Network (NCCN) Guidelines: Myeloproliferative Neoplasms  

As myeloproliferative neoplasms carry a significant symptom burden and oftentimes can require lifelong care coordination and close monitoring, hear how a strong multidisciplinary approach can impact shared decision-making and patient engagement. In this episode, CANCER BUZZ speaks with speaks with Andrew Kuykendall, MD, assistant member of the Department of Malignant Hematology at Moffitt Cancer Center in Tampa, Fla. and Katherine Mast, BSN, RN at Moffit Cancer Center about the impact of multidisciplinary coordination on patient care and outcomes for patients with myeloproliferative neoplasms. “When we talk about shared-decision making, I think we can talk about it in the sense of sharing that decision-making with the patient, and also sharing it with the entire [multidisciplinary] team. We like to create that engagement where we [the multidisciplinary team] are all there together—to recount what is going on, refocus what our goals of therapy are, discuss what the different options are, and then put it in the patient's hands to say ‘of these options, what do you think makes the most sense for what your goals are?'” – Andrew Kuykendall, MD “Where we can make some of the biggest impact is having people on our team who really understand what it's like to have an MPN because we see this group of patients constantly. Having one person that they can come to is wonderful, but having multiple people that are on their team that they know are there to help and answer questions can be really profoundly impactful, especially if they have a rare disease and their local hematologist/oncologist may not know as much about it.” – Katherine Mast, BSN, RN This is the third video podcast in a four-episode series on myeloproliferative neoplasms in connection with the education program “Advancing Care for Patients with Myeloproliferative Neoplasms (MPNs).” This episode is supported by Incyte. Guests: Andrew Kuykendall, MD,  Assistant Member, Department of Malignant Hematology Moffitt Cancer Center Tampa, FL  Katherine Mast, BSN, RN  Registered Nurse Moffitt Cancer Center Tampa, FL Resources: Myeloproliferative Neoplasms (cancersupportcommunity.org) National Comprehensive Cancer Network (NCCN) Guidelines: Myeloproliferative Neoplasms  

Dr. Dan Nahrwold had heard of CLC's life-changing "All In" discipleship curriculum but experiencing it for himself surpassed all his expectations. Dan shares about how God planted seeds in his life several years earlier, and how those seeds led to eventually starting his own "All In" group after moving to Tampa, FL. We spend some time discussing the significance of relationships in men's discipleship and how that accountability impacts our approach to work and our careers.Dr. Daniel Nahrwold is an Assistant Member in the Moffitt Cancer Center Department of Anesthesiology. Dr. Nahrwold earned his MD at the Indiana University School of Medicine. He then completed an Anesthesiology Residency at Vanderbilt University Medical Center followed by a Critical Care Medicine Fellowship at the University of California, San Francisco. Dr. Nahrwold's clinical interests are in acute pain management, ultrasound-guided regional anesthesia, biomedical informatics, and critical care medicine. His research interests are in advancing technology and anesthetic techniques to improve perioperative quality outcomes.SHOW NOTES:Contact Dr. Dan Nahrwold: daniel.nahrwold@gmail.comLearn more about CLC's All In Discipleship curriculum: https://www.clchq.org/all-inContact Chris Bolinger: https://chrisbolinger.com/author/CLC Website: https://www.clchq.org/Contact Mike Hatch: mhatch@clchq.orgMen's Devotional: "Daily Strength for Men" (https://www.amazon.com/Daily-Strength-Men-365-Day-Devotional-ebook/dp/B07N9P7DRD)

Dr. Lydia Finley is an Assistant Member of the Cell Biology Program at Memorial Sloan Kettering Cancer Center. The Finley lab investigates how cellular metabolic pathways regulate cell fate decisions in stem cells and cancer cells. She talks about the metabolic profiles and needs of different cell types, her lab's discovery of an alternate TCA cycle, and how track and field led her to pursue metabolism research.

Dr. Malia Gehan is an Assistant Member at the Donald Danforth Plant Science Center. Her research examines how to improve crops in terms of their response to temperature stress and other abiotic stresses. She is does this through examining natural variation in plants. There are many plants that are highly resilient in different environmental conditions but are not edible. Malia is investigating how to take useful traits from these hardy, weedy plants and incorporate them into crops. Outside of science, Malia spends her free time with her two cats and her husband, who is also a scientist. They enjoy lounging around at home, as well as walking around their neighborhood near the Missouri Botanical Garden. Malia also has fun cooking, going to the movies, and watching TV. She received her undergraduate training in Biology from Willamette University and her PhD in Plant Biology from Michigan State University. Afterwards, Malia was awarded a National Science Foundation Plant Genome Initiative Postdoctoral Fellowship working at the Donald Danforth Plant Science Center, and she subsequently worked as a Research Scientist there before accepting her new position. Malia is with us today to tell us all about her journey through life and science.

In this episode, Frauke sits down with experimental psychologist, Assistant Director, and Assistant Member of the Monell Chemical Senses Center Valentina Parma, PhD to discuss where we are today in terms of testing and diagnosing the health of a person's sense of smell. Valentina shares how COVID became a magnifying glass for connecting the sense of smell to our health, and how unprepared we all were in our ability to assess olfactory health when smell loss became a key symptom of the virus. She explains how screening for small, incremental changes in olfactory function (and dysfunction) from an early age has the potential to help doctors detect olfactory disorders, then monitor their progress, and even intervene early in the diagnosis of such illnesses as Alzheimer's, Parkinson's, and Autism Spectrum Disorder. Valentina also provides information on an exciting new rapid smell test being developed by Monell scientists and collaborators called SCENTinel, and reveals her mission to get this quick and inexpensive screening tool into every doctor's office around the world. Frauke and Valentina also discuss the important collaborative work being done by the GCCR and the 3 simple tests you can do at home to assess your own olfactory health. Learn more about the rapid screening tool SCENTinel: https://monell.org/smell-check/ Evaluate your olfactory health using the GCCR surveys (3 tools): https://gcchemosensr.org/ Visit the Monell website and learn how you can talk to children about the senses of smell and taste (science activity): https://monell.org/covid-19-resources/ Learn how you can participate in Monell research projects: https://monell.org/covid-19-resources/ Learn about Frauke's 21-Day Smell Training Program: https://www.falkaromatherapy.com/smelltraining Get Frauke's free Smell To Be Well audio training Get Frauke's free Aromatic Wellness Kit Follow Frauke on Instagram @falkaromatherapy Follow Frauke on Facebook @falkaromatherapy Visit the FALK Aromatherapy website: www.falkaromatherapy.com Check out Frauke's Scent*Tattoo project: www.scenttattoo.com --- Send in a voice message: https://anchor.fm/anaromaticlife/message

Our new podcast format with member's only bonus episodes every second week debuts. Alex interviews Orla about what it's like watching Girls separated from the weekly episode discourse. Alex and Orla discuss the difficult of reading shows with empathy for terrible people, great acting, and the difference between Hana and Lena Dunham. Show notes: You can listen to our first 15 bonus episodes by becoming a Seventh Row member Read Alex's 2017 review of Paterson Read Alex's 2016 review of City of Tiny Lights Related Episodes Ep. 97: The Films and TV of Desiree Akhavan Ep. 94: Looking Ep. 73: Explorations of rape culture in Promising Young Woman and The Assistant (Member's Only) Ep. 54: Kris Rey's thirtysomethings: I Used to Go Here and Unexpected (Member's Only) Follow Seventh Row on Twitter, Instagram, and Facebook, and read our articles at seventh-row.com.

We discuss two sci-fi-ish romantic comedies, Maria Schrader's I'm Your Man, which was one of our favourite films from the Berlinale earlier this year, and Richard Curtis' About Time, about which we have complicated feelings. This episode features Editor-in-Chief Alex Heeney, Executive Editor Orla Smith, and staff writer Lena Wilson. Show Notes: Read Alex's review of I'm Your Man Register for The Seventh Circle, a symposium on gender, sexuality, and disability in horror cinema. Sign up for updates on the first book to ever be published on the films of Norwegian filmmaker Joachim Trier Related Episodes: Ep. 110: Brief encounters: Weekend and End of the Century Ep. 92: Commodifying Women: Sugar Daddy and An Easy Girl Ep. 89: Coming of Age at Forty: Spinster and The Forty-Year-Old Version Ep. 73: Explorations of rape culture in Promising Young Woman and The Assistant (Member's Only) Ep. 61: Toxic male privilege in The Riot Club and What Richard Did (Member's Only) Follow Seventh Row on Twitter, Instagram, and Facebook, and read our articles at seventh-row.com.

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and David Sallman, MD, Assistant Member, Department of Malignant Hematology, Moffitt Cancer Center discuss CAR T as it pertains to clinical advances in leukemia

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and David Sallman, MD, Assistant Member, Department of Malignant Hematology, Moffitt Cancer Center discuss CAR T as it pertains to clinical advances in leukemia

Resistance to treatment – it’s one of the most important issues in cancer research. If cancer cells aren’t killed during treatment, either because they weren’t affected or because they changed enough to survive the treatment, it could lead to cancer recurrence. Tuomas Tammela, MD, PhD, has an American Cancer Society grant to explore resistance to treatment in lung adenocarcinoma, the most common subtype of lung cancer. In this conversation he walks us through new findings from his lab on the “highly plastic state” of certain cells in tumors. He explains how this relates to tumor heterogeneity, why this is a problem in lung cancer and other cancer types, and how it could be used in combination therapies. Tuomas Tammela, MD, PhD, is Assistant Member at the Sloan Kettering Institute at Memorial Sloan-Kettering Cancer Center. 3:01 – What does it mean for cancer to become resistant to treatment? 5:24 – What does resistance to treatment mean in terms of the cellular makeup of a tumor? 7:21 – A helpful way to understand “tumor heterogeneity” 9:31 – What it means for cells to be in a “highly plastic state” and why that’s importance to treatment resistance and cancer progression 13:05 – Is the “highly plastic cell state” seen in different cancer types and… 14:46 – …could it be targeted therapeutically? 16:51 – How tumor heterogeneity impacts treatment resistance in lung cancer 20:42 - If later stage lung cancer tumors are more heterogenous, what could help us understand how to treat them? 25:12 – On how American Cancer Society funding has impacted his research 26:41 – A message he’d like to share with cancer patients and caregivers

90% of cancer deaths are caused by metastasis. What is metastasis? Why are metastatic cancer cells so hard to target? Are they different than the cancer cells in the primary tumor? What opportunities for treatment are there? To answer these questions we spoke with former American Cancer Society grantee Karuna Ganesh, MD, PhD, a physician scientist and Assistant Member at Memorial Sloan Kettering Cancer Center. Dr. Ganesh is a GI medical oncologist who runs a lab that’s trying to understand what it is about metastatic cancer cells that make them so deadly and how we can target them. 1:20 – A simple, clear explanation of what metastasis is 2:31 – Why would cancer cells leave their neighbors and seek alternative housing? Moving is stressful; why not just stay put? 5:14 – On why the concept of “wound healing” is so important in cancer research 9:30 – How metastasis is wound healing gone wrong—cellular processes used in a good way for wound healing could be used in a bad way in metastasis 14:56 - Are the cancer cells that metastasize the ‘same’ in their new location as they were in their old one? 18:23 – What are targeted therapies? 20:14 – If cancer cells that ‘move’ and cancer cells that ‘stay’ are different, how might we use targeted therapies to treat metastatic disease? 21:21 – Why she’s so excited about the state of the field 23:11 – The impact of ACS funding on her career 24:49 – Her message for cancer patients and caregivers

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Michael Jain, MD, Assistant Member, Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, discuss the role of CAR-T and the treatment of lymphoma and off-the-shelf CAR-T

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Michael Jain, MD, Assistant Member, Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, discuss the role of CAR-T and the treatment of lymphoma and off-the-shelf CAR-T

Guest: Dr. Jennifer Adair is an Assistant Member in the Clinical Research Division at Fred Hutchinson Cancer Research Center. Her lab uses a combination of cell biology, molecular biology, chemistry, engineering, nanomedicine and bioinformatics to…

Immunotherapy is a major class of therapy that continues to expand in the myeloma clinic. Dr. Alexander Leshokin of Memorial Sloan Kettering Cancer Center explains the various types of immunotherapies: transplant, monoclonal antibodies, bi-specific antibodies, antibody drug conjugates, cellular therapies like CAR T, vaccines and where each type of treatment is at in the various stages of development.  Dr, Alexander Lesokhin is Assistant Attending Physician at Memorial Hospital for Cancer and Allied Diseases and Assistant Member of Memorial Sloan Kettering Cancer Center. He is an active member of ASCO and ASH and has oversight of fellows and residents in the transplant, lymphoma and myeloma units. Dr. Lesokhin performs significant immunotherapy research and is engaged in studies to perform work in the lab that will bridge to the clinic as to why cancer cells can evade the bone marrow derived tumor-infiltrating cells. He is also performing research on checkpoint inhibitors and why T cells get exhausted, particularly following stem cell transplant.  Thanks to our episode sponsor, Celgene.   

Dr. Malia Gehan is a new Assistant Member at the Donald Danforth Plant Science Center. She received her undergraduate training in Biology from Willamette University and her PhD in Plant Biology from Michigan State University. Afterwards, Malia was awarded a National Science Foundation Plant Genome Initiative Postdoctoral Fellowship working at the Donald Danforth Plant Science Center, and she subsequently worked as a Research Scientist there before accepting her new position. Malia is with us today to tell us all about her journey through life and science.

Join us for our second interview on Myeloma Crowd Radio highlighting the new Myeloma Crowd Research Initiative on high-risk myeloma. As part of this series, Dr. Guenther Koehne, MD, PhD of the Memorial Sloan Kettering Cancer Center will share his use of a T cell vaccine with an allogeneic transplant to provide outstanding results, even in plasma leukemia patients. His research pulls out T cells, marks them with a tag to target the WT1 protein, and are given back. He will describe how this works, the impact he has seen so far, the stage of his clinical trial and the work left to do to make this an available therapy for high-risk myeloma patients.  Dr. Guenther Kohene, MD, PhD is Medical Director of the Cell Therapy Laboratory in the Bone Marrow Transplantation Laboratory at Sloan Kettering. He is also Assistant Member and Assistant Attending Physician in the Allogeneic Bone Marrow Transplantation Service. He is Assistant Professor of the Joan and Sanford Weill Medical College of Cornell University. He leads research at the BMT Department/Immunology Program to develop adoptive immunotherapeutic strategies for post-transplant blood disorders. He has particular expertise in the creation and monitoring of antigen-specific T cell responses in these patients. He is the Principal Investigator in active clinical trials using adoptive cell therapy following allogeneic stem cell transplants for multiple myeloma and plasma cell leukemia patients. He obtained his medical degree at the University of Hamburg, Germany and has been at Memorial Sloan Kettering Cancer Center permanently since 2005. Special thanks to our Myeloma Crowd Radio Episode sponsor, Takeda Oncology.

Learn How The Intake Of Raw Broccoli May Improve Bladder Cancer Survival Dr. Li Tang is an Assistant Member in the Department of Cancer Prevention and Control at Roswell Park Cancer Institute. Her educational background is in medicine, nutrition, cancer biology, and epidemiology. She obtained her Ph.D. degree in Cancer Prevention and Pathology, and received postdoctoral training in Nutritional Epidemiology. Dr. Tang is engaged in the molecular epidemiological study of cancer, with focus on cancer recurrence and survival. Her research interest is to understand the interactive roles of genetic and dietary factors in cancer prognosis. Her primary focus is on cruciferous vegetables and their key anti-cancer effectors, the phytochemical isothiocyanates. Dr. Tang's recent publications: "Intake of Cruciferous Vegetables Modifies Bladder Cancer Survival." Cancer Epidemiol Biomarkers Prev. 2010 Jul;19(7):1806-11. Epub 2010 Jun 15 and "Consumption of Raw Cruciferous Vegetables is Inversely Associated With Bladder Cancer Risk." Cancer Epidemiol Biomarkers Prev. 2008 Apr;17(4):938-44. Download or Open: